Hyperfine’s (HYPR) “Buy” Rating Reiterated at BTIG Research

BTIG Research restated their buy rating on shares of Hyperfine (NASDAQ:HYPR) in a report released on Tuesday morning,Benzinga reports. They currently have a $2.00 price objective on the stock.

A number of other equities research analysts have also recently weighed in on the stock. B. Riley Financial restated a “buy” rating and set a $1.60 price objective (down from $2.00) on shares of Hyperfine in a research note on Monday, August 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Hyperfine in a research report on Friday, July 17th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $2.03.

Hyperfine Stock Performance

Shares of HYPR stock opened at $0.80 on Tuesday. Hyperfine has a 12-month low of $0.75 and a 12-month high of $2.22. The company has a debt-to-equity ratio of 0.36, a current ratio of 6.15 and a quick ratio of 5.45. The firm has a market capitalization of $84.41 million, a price-to-earnings ratio of -2.09 and a beta of 1.41. The business has a 50 day simple moving average of $0.88 and a 200 day simple moving average of $1.18.

Hyperfine (NASDAQ:HYPR) last announced its earnings results on Thursday, August 6th. The company reported ($0.09) earnings per share for the quarter, meeting the consensus estimate of ($0.09). Hyperfine had a negative return on equity of 97.88% and a negative net margin of 210.75%.The firm had revenue of $3.90 million for the quarter, compared to the consensus estimate of $4.13 million. On average, equities research analysts anticipate that Hyperfine will post -0.34 EPS for the current year.

Hedge Funds Weigh In On Hyperfine

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HYPR. Walleye Capital LLC raised its stake in shares of Hyperfine by 3.4% in the 1st quarter. Walleye Capital LLC now owns 223,988 shares of the company’s stock worth $242,000 after buying an additional 7,330 shares in the last quarter. Bank of New York Mellon Corp bought a new position in Hyperfine during the second quarter valued at about $419,000. Renaissance Technologies LLC boosted its stake in Hyperfine by 100.2% during the first quarter. Renaissance Technologies LLC now owns 730,233 shares of the company’s stock valued at $789,000 after buying an additional 365,490 shares in the last quarter. Finally, Catalio Capital Management LP grew its holdings in Hyperfine by 92.8% during the fourth quarter. Catalio Capital Management LP now owns 1,320,041 shares of the company’s stock worth $1,293,000 after acquiring an additional 635,500 shares during the period. 15.03% of the stock is owned by institutional investors.

Hyperfine Company Profile

Hyperfine, Inc is a medical technology company that develops portable magnetic resonance imaging (MRI) systems for use at the point of care. Its flagship product, the Swoop Portable MR Imaging System, is designed to bring brain imaging directly to patients in settings such as intensive care units, emergency departments, hospitals and other clinical environments.

The Swoop system is intended to support rapid assessment of neurological conditions, including stroke, brain injury and other disorders.